Journal Article Summary
The article discusses the potential of ionic liquid forms of antiviral medications, particularly in the context of the ongoing COVID-19 pandemic. With no FDA-approved treatments specifically for COVID-19 at the time of writing, the authors emphasize the need for effective antiviral therapies. They highlight that many existing antiviral drugs face challenges such as poor solubility and polymorphic transformations, which can affect their safety and efficacy. The authors argue that ionic liquids, which are liquid salts that can incorporate active pharmaceutical ingredients (APIs), could offer a solution to these issues by improving drug properties and bioavailability.
To explore this concept, the authors reviewed existing literature and presented case studies on two antiviral ionic liquids: acyclovir and GSK2838232. They found that ionic liquid forms of these drugs significantly enhanced their solubility compared to traditional formulations. For instance, acyclovir in ionic liquid form showed a solubility increase of up to 650 times compared to its neutral form. The authors advocate for the pharmaceutical industry to consider these ionic liquid formulations as a means to innovate and improve the delivery and effectiveness of antiviral medications.
However, the article also addresses several limitations and concerns regarding the use of ionic liquids in pharmaceuticals. These include misconceptions about their physical properties, potential toxicity, and the lack of established regulatory guidelines for their production and characterization. The authors suggest that patients and caregivers should discuss these emerging treatment options with healthcare professionals, particularly regarding the safety and efficacy of ionic liquid formulations. They emphasize the importance of overcoming existing myths and regulatory hurdles to fully realize the potential benefits of ionic liquid antiviral medications.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Shamshina Julia L., Rogers Robin D.. Are Myths and Preconceptions Preventing Us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis?. International Journal of Molecular Sciences 2020. DOI: 10.3390/ijms21176002. PMID: 32825444. PMCID: PMC7503643.
Featured Pill Pals Product
Docusate Sodium /Senna 8.6-50 mg Tablets 100 Count --- Generic for Peri-Colace --- Rugby Pharma --- Over The Counter
Docusate Sodium /Senna 8.6-50 mg Tablets 100 Count — Generic for Peri-Colace — Rugby Pharma — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
